Table 3 Frequent concurrence of PIK3CA mutations and loss of ARID1A immunoreactivity in the endometriosis-associated ovarian clear-cell carcinoma development

From: Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations

Case no. (patient's age (years))

Status of PIK3CA/immunoreaction for ARID1A

 

Clinical stage of disease a

Non-atypical endometriosis

Atypical endometriosis

Clear-cell carcinoma

5 (49)

I

Mut/deficient

Mut/deficient

Mut/deficient

6 (48)

I

Wt/intact

Wt/deficient

Mut/deficient

8 (56)

IV

Mut/deficient

−/−

Mut/deficient

12 (53)

I

Wt/intact

Mut/intact

Mut/intact

13 (41)

IV

−/−

Mut/deficient

Mut/deficient

14 (51)

I

Mut/deficient

Mut/deficient

Mut/deficient

15 (58)

II

−/−

Mut/deficient

Mut/deficient

17 (48)

I

Mut/deficient

Mut/deficient

Mut/deficient

18 (53)

I

Mut/deficient

Mut/deficient

Mut/deficient

20 (50)

III

Mut/deficient

−/−

Mut/deficient

  1. aClinical stages of disease defined by the International Federation of Gynecology and Obstetrics.
  2. Mut, somatic mutations (+); Wt, wild type for exon 9 and 20; −/−, corresponding components were not histologically identified.
  3. The data of this study combined with those obtained from our previous study.15
Back to article page